BSECompany Update2d ago · 16 Nov 2026, 06:52 pm

Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026

Orchid Pharma Ltd · 524372

✦ AI Summary▲ PositiveResults

Orchid Pharma Ltd has released its Investor Presentation for Q2 FY 2026-27, showcasing its financial performance and business prospects. The company has made significant progress in its anti-infectives business, with a strong presence in regulated markets and a focus on long-term growth.

Analysis Scores

Earnings Impact8/10
Growth Catalyst9/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk5/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Investor Presentation

Attachments (1)

📄

b1b3f007-d442-4de3-a55b-0f3bc3f2d5fb.pdf

pdf

Download →
View document text
OrchidPharm~W -- A DhanukaGroup Company -----------------------'-------------- November 16, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Requlations, 2015 (ii) SEBI Circular No. SEBIIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sub: Investors Presentation- Ouarter II of F.Y. 2026-27, ended on September 30, 2026 - Orchid Pharma Limited ("the Company") Dear Sir/Madam, With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024 and in continuation to our earlier intimation, dated November 12, 2026, regarding the Analysts/Investors Earning Call scheduled to be held on November 17, 2026 at 04:30 P.M. (1ST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-II of Financial Year 2026-27, ended on September 30, 2026. The Investor Presentation is also made available on the website of the Company at https:llwww.orchidpharma.com(jnvestors You are requested to take the above intimation on record. Thanking You, For Orchid Pharma Limited Kapil Dayya Company Secretary & Compliance Officer Mem. No.- F10698 Encl. as above +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. FROM Soil to Vial Nature Inspired Fermentation KSMs & API API Formulations Finished Dosage Origins & Biotransformation Process Manufacturing & Fill Finish For A Healthier World Development 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared byOrchid Pharma Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's levels of activity, performance or achievements could differ materially and adversely fromresults expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. 2026 orchidpharma.com 02 Orchid Pharma Limited A significantly large anti- A strong participant in infectives business built on selected high-value and Positioned for sustained an integrated foundation regulated opportunities long-term growth Scale + Integration Regulated Markets Structural Growth One of the most 1 3 5 integrated anti-infective platform globally Built on 30 years of cephalosporin expertise. Proven by EXBLIFEP -India's only novel antibiotic. Anchored by India's only USFDA sterile cephalosporin approval. Extending into AMR and regulated markets. A differentiated cephalosporin A business combining scale, platform spanning KSM to integration, innovation and finished dosage disciplined expansion Full Value Chain Four Pillars 2026 orchidpharma.com 03 Orchid is at an inflection point The merger is complete and the platform is coming An Integrated together as one Cephalosporin Platform The core API business is ready to create long-term value Multiple growth engines are moving from concept to execution across KSM, FDF, and Innovative drug products 2026 orchidpharma.com 04 S T R A T E G I C A M A L G A M A T I O N Two entities. One Orchid. DLL OPL ORCHID Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. under the NCLT-sanctioned Scheme. APPOINTED DATE EFFECTIVE DATE 1 April 2024 10 July 2026 2026 orchidpharma.com 05 EXBLIFEP · BUSINESS DEVELOPMENT Signed licensing partnerships Pharmasyntez Laboratorio Libra RUSSIA · 1 MARKET LATIN AMERICA · 9 MARKETS US$ 178 M US$ 80 M Estimated sales potential Estimated sales potential Markets Covered: Russian Federation Markets Covered: Chile · Uruguay · Panama · El Salvador · Guatemala · Ecuador · Honduras · Paraguay · Costa Rica COMBINED US$ 258 M across 10 markets · 2 signed partners 2026 orchidpharma.com 06 Financial Performance Q2 FY27 2026 orchidpharma.com 07 Q2 FY27 Financial Performance : Standalone (RsCr) (Amt.in Cr.) Q2-27 Q2-26 % Change H1-27 H1-26 % Change Revenuefrom 341 298 +14% 645 562 +15% Operations Other Income 29 16 +76% 39 32 +20% COGS 208 207 413 390 Employee Exp 33 31 59 58 Other Exp 77 57 135 115 EBITDA 52 20 +148% 77 31 +151% % to Sales 15% 7% 12% 5% Interest 4 3 6 5 +21% Depreciation 11 11 22 21 Exceptional Items – – – – PAT 37 7 49 5 2026 orchidpharma.com 08 Q2 FY27 Financial Performance : Standalone (Rs Cr) Total Revenue EBITDA PAT 341 52 37 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Gross Margin EBITDA Margin (%) Q2FY26 Q2FY27 Q2FY26 Q2FY27 2026 orchidpharma.com 09 H1 FY27 Financial Performance : Standalone (Rs Cr) Total Revenue EBITDA PAT 645 77 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 Gross Margin EBITDA Margin (%) 2026 orchidpharma.com 010 H1FY26 H1FY27 H1FY26 H1FY27 Profit & Loss Statement (Standalone) (Rs Cr) Q2 FY27 Q1 FY27 Q2 FY26 H1 FY27 H1 FY26 FY26 Particulars Sep 2026 Jun 2026 Sep 2025 Sep 2026 Sep 2025 Year ended Income Revenue from Operations 341.27 304.17 298.46 645.44 561.64 1,232.78 Other Income 28.63 10.05 16.29 38.68 32.34 56.49 Total Income 369.90 314.22 314.75 684.12 593.99 1,289.27 Expenses Cost of Materials Con [Showing first 8,000 characters — download PDF for full document]